Scheme for Strengthening of Medical Device Industry (SMDI) - Marginal Investment Scheme for Reducing Import Dependence (MISRID)
Department of Pharmaceuticals · Central government
SMDI offers a capital subsidy to manufacturers of key medical device components and raw materials, aiming to cut import dependency.
Closed. Applications closed on 24 July 2026. The details below describe the most recent cycle.
Key facts
- Subsidy amount
- Up to ₹10,00,00,000
- Instrument
- Subsidy
- Deadline
- 24 July 2026
- Disbursement
- Reimbursed after spend
About this scheme
## Scheme for Strengthening of Medical Device Industry (SMDI)
The Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Government of India, runs the Scheme for Strengthening of Medical Device Industry (SMDI), which works to build India's self-reliance in the medical device sector. The Marginal Investment Scheme for Reducing Import Dependence (MISRID) sits within SMDI and targets the localisation of components, raw materials and accessories needed to manufacture medical devices, in-vitro diagnostics (IVDs) included. Indian medical device manufacturing has long depended on imported inputs for these items, which exposes supply chains to risk and pushes up production costs. MISRID offers financial incentives to domestic companies that invest in making such items, so that this import dependence is reduced.
The scheme's aim is an indigenous medical device manufacturing ecosystem that strengthens India's ability to produce quality medical devices at affordable prices. SMDI-MISRID supports local production of key components — sensors, embedded systems, optical filters, electrodes and medical-grade materials among them — and in doing so seeks to encourage innovation, generate employment and establish India as a global hub for medical device manufacturing. The push is in line with the 'Make in India' vision and supports public health by keeping essential medical devices available within the country, particularly during global health crises.
Who can apply
- Eligible business forms
- Private limited company, Limited liability partnership, One person company, Partnership firm, Sole proprietorship
- Udyam registration
- Not specified
- MSME registration
- Not specified
- DPIIT startup recognition
- Not specified
- GST registration
- Not specified
- Where the business may be based
- Not restricted
- Central or State Government organisations, companies or LLPs, and Special Purpose Vehicles (SPVs) registered in India under the Companies Act or the Societies Registration Act are eligible to apply. - Medical device or in-vitro diagnostic manufacturers qualify, whether they already operate facilities or intend to produce key components, input materials or accessories. - Manufacturers of critical raw materials — for example polymer, glass, metal, textile or paper for medical grade use — are also eligible. - Importers who intend to move into manufacturing any medical device or IVD on the GTE list may apply.
How to apply
1. Go to the official SMDI portal at https://smdi.lsssdc.in/. 2. Open the application section for the Marginal Investment Scheme for Reducing Import Dependence (MISRID). 3. Register your organisation and complete the online application form, providing all details sought. 4. Upload the supporting documents required, which usually comprise company registration certificates, financial statements, a detailed project proposal, investment plans, and technical specifications of the components or materials to be manufactured. 5. File your application before the deadline of July 24, 2026. 6. Track the status of your application on the portal and reply to any queries raised by the scheme administrators. 7. Applicants who are shortlisted move on to the evaluation stages, which involve technical review and committee appraisals.
How applications are assessed
Applications are first appraised by the Project Management Agency (PMA), which checks that each submission is complete and meets the basic criteria. A Technical Committee then examines the proposed manufacturing projects for technical feasibility, innovation and strategic importance. Final approval rests with the Scheme Steering Committee, which confirms that selected projects align with the scheme's goals of strengthening the medical device industry and reducing import dependence.
Frequently asked questions
What is the primary objective of the MISRID scheme?
The scheme aims to cut India's reliance on imports by encouraging domestic manufacture of essential components, raw materials and accessories used in medical devices, in-vitro diagnostic devices included.
Who is eligible to apply for this scheme?
Central and State Government organisations, Companies or LLPs registered in India, and Special Purpose Vehicles (SPVs) registered under the Companies Act or the Societies Registration Act are all eligible to apply, which covers manufacturers of medical devices, IVDs and critical raw materials as well as importers intending to shift to manufacturing.
What is the maximum subsidy amount I can receive?
Capital subsidy is capped at ₹10 Crore and is paid as reimbursement. The applicable rate — 20%, 15% or 10% — is set by the company's annual turnover, with smaller companies receiving the higher percentage of their investment.
What kind of activities are eligible for this subsidy?
Eligible activities cover the manufacture of key components, raw materials and accessories for medical devices and IVDs, including sensors, embedded systems, optical filters, electrodes, antigens/antibodies, polymer tubing, metal tubing and medical-grade packaging materials.
Is co-financing required for this scheme?
Yes — the incentive is a capital subsidy paid on a reimbursement basis, so the applicant must fund the initial investment and co-finance it, with a percentage of that investment then reimbursed.
What is the project completion timeline?
Approved projects must be completed within two years of final approval, though a one-year extension may be allowed in specific circumstances.
Sectors
- Health Lifesciences
- Medical Devices
- Healthcare Manufacturing
- Import Substitution
- Capital Subsidy
- Invitro Diagnostics
- Pharmaceuticals
Details last verified on 12 November 2026. Source: the issuer's published information.